News
After phase 3 clean sweep, Roche plans oral BTK filing in MS
Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?
Sunday 26 July 2026
